Caribou Biosciences
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. Utilizing proprietary CRISPR genome-editing technology, including its Cas12a chRDNA platform, the company advances off-the-shelf CAR-T cell therapies aimed at broad patient access and rapid treatment, especially for hematologic malignancies. Led by a dedicated leadership team and supported by extensive IP licensing, Caribou is committed to innovation in genome editing and cell therapy development.
Industries
Nr. of Employees
medium (51-250)
Caribou Biosciences
Patents
Products
Allogeneic anti-CD19 CAR-T therapy with PD-1 knockout (clinical-stage)
An off-the-shelf anti-CD19 CAR-T therapy engineered via multiplex genome editing to remove endogenous TCR, site-specifically insert the CAR, and knock out PD-1 to limit exhaustion and enhance antitumor activity; under evaluation in a Phase 1 clinical trial for relapsed/refractory B cell non-Hodgkin lymphoma.
Allogeneic anti-BCMA CAR-T therapy with immune cloaking (clinical-stage)
An off-the-shelf anti-BCMA CAR-T therapy engineered with multiplex edits including TRAC knockout, site-specific CAR insertion, and B2M knockout combined with B2M–HLA-E fusion transgene insertion to reduce host T and NK cell-mediated rejection; under evaluation in a Phase 1 trial for relapsed/refractory multiple myeloma.
Allogeneic anti-CLL-1 CAR-T therapy (clinical-stage)
An allogeneic anti-CLL-1 CAR-T product engineered with next-generation genome-editing to resist immunosuppressive tumor microenvironments and immune-mediated rejection; presented in preclinical and clinical meeting materials for acute myeloid leukemia.
iPSC-derived allogeneic CAR-NK cell therapy for solid tumors (preclinical)
An induced pluripotent stem cell (iPSC)-derived, allogeneic CAR-NK cell therapy engineered for enhanced activity against solid tumors demonstrated in preclinical presentations.
CB-011
CB-011 is a genome-edited allogeneic anti-B cell maturation antigen (BCMA) CAR-T cell product candidate engineered with next-generation CRISPR technology to knock out B2M and express a B2M-HLA-E fusion transgene for the treatment of relapsed or refractory multiple myeloma.
Vispa-cel
Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is a lead clinical-stage allogeneic anti-CD19 CAR-T cell therapy utilizing a PD-1 knockout to limit premature CAR-T cell exhaustion for the treatment of relapsed or refractory B-NHL.
Allogeneic anti-CD19 CAR-T therapy with PD-1 knockout (clinical-stage)
An off-the-shelf anti-CD19 CAR-T therapy engineered via multiplex genome editing to remove endogenous TCR, site-specifically insert the CAR, and knock out PD-1 to limit exhaustion and enhance antitumor activity; under evaluation in a Phase 1 clinical trial for relapsed/refractory B cell non-Hodgkin lymphoma.
Allogeneic anti-BCMA CAR-T therapy with immune cloaking (clinical-stage)
An off-the-shelf anti-BCMA CAR-T therapy engineered with multiplex edits including TRAC knockout, site-specific CAR insertion, and B2M knockout combined with B2M–HLA-E fusion transgene insertion to reduce host T and NK cell-mediated rejection; under evaluation in a Phase 1 trial for relapsed/refractory multiple myeloma.
Allogeneic anti-CLL-1 CAR-T therapy (clinical-stage)
An allogeneic anti-CLL-1 CAR-T product engineered with next-generation genome-editing to resist immunosuppressive tumor microenvironments and immune-mediated rejection; presented in preclinical and clinical meeting materials for acute myeloid leukemia.
iPSC-derived allogeneic CAR-NK cell therapy for solid tumors (preclinical)
An induced pluripotent stem cell (iPSC)-derived, allogeneic CAR-NK cell therapy engineered for enhanced activity against solid tumors demonstrated in preclinical presentations.
CB-011
CB-011 is a genome-edited allogeneic anti-B cell maturation antigen (BCMA) CAR-T cell product candidate engineered with next-generation CRISPR technology to knock out B2M and express a B2M-HLA-E fusion transgene for the treatment of relapsed or refractory multiple myeloma.
Vispa-cel
Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is a lead clinical-stage allogeneic anti-CD19 CAR-T cell therapy utilizing a PD-1 knockout to limit premature CAR-T cell exhaustion for the treatment of relapsed or refractory B-NHL.
Services
Licensing and partnering services for CRISPR- and Cas-based intellectual property for applications in research tools, transgenic animals, internal research, diagnostics, and industrial biotechnology.
Licensing and partnering services for CRISPR- and Cas-based intellectual property for applications in research tools, transgenic animals, internal research, diagnostics, and industrial biotechnology.
Expertise Areas
- Clinical trial management (Phase 1 multicenter studies)
- Allogeneic cell therapy development
- Genome-editing platform development
- Preclinical translational research and animal models
Key Technologies
- CRISPR hybrid RNA-DNA guides
- Cas9 genome editing
- Cas12a genome editing
- Site-specific gene insertion